Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Arcadia Biosciences in a research report on Friday, April 5th.

Arcadia Biosciences Trading Up 0.5 %

Shares of Arcadia Biosciences stock opened at $2.02 on Tuesday. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $6.50. The firm’s 50-day moving average price is $2.22 and its two-hundred day moving average price is $2.67. The stock has a market capitalization of $2.75 million, a price-to-earnings ratio of -0.14 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings results on Thursday, March 28th. The basic materials company reported ($2.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.20. The firm had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $1.80 million. Arcadia Biosciences had a negative return on equity of 81.56% and a negative net margin of 246.80%. As a group, equities research analysts predict that Arcadia Biosciences will post -5.01 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.